An Open Label, Single Arm Observational Study to Assess the Efficacy of Zandu Rhumasyl Maxx - A Topical Ayurvedic Liniment in Adult Subjects for The Management of Pain & Inflammation Associated with Musculoskeletal Joint & Muscles - NIL

Start Date25 Apr 2025

Sponsor / Collaborator

Emami Ltd.

CTRI/2024/12/077617

/ Not yet recruitingPhase 4

Evaluation of the safety & efficacy of Zandu Chyawanprash debility & symptoms associated with weak immunity - NIL

Start Date19 Dec 2024

Sponsor / Collaborator

Emami Ltd.

CTRI/2024/10/075385

/ Not yet recruitingPhase 4

An open label, clinical study to evaluate the safety and efficacy of Zandu Kesri Jivan to improve immunity, strength, stamina and energy. - NIL

Start Date22 Oct 2024

Sponsor / Collaborator

Emami Ltd.

100 Clinical Results associated with Emami Ltd.

0 Patents (Medical) associated with Emami Ltd.

Literatures (Medical) associated with Emami Ltd.

01 Dec 2025·Molecular Biology Reports

Internal transcribed spacer (ITS): The powerful DNA barcode and phylogenetic marker for successful authentication of Withania somnifera

Article

Author: Dhabal, Sukhamoy ; Banerjee, Dipankar ; Katiyar, Chandra Kant ; Rai, Rajiva Kumar ; Dubey, Sunil Kumar ; Chakrabarty, Anirban Kr

BACKGROUNDUnderstanding the evolutionary history of plants and accurately identifying biologically important species and their families is crucial for the herbal and Ayurvedic industries. The genetic approach by DNA barcoding plays a pivotal role in accurate species identification, authentication and quality control. Due to various therapeutic properties, Withania somnifera has been used worldwide in traditional systems of medicine for centuries including Ayurveda and Unani. The increasing demand for W. somnifera products has led to concerns regarding the authenticity and quality of commercial herbal preparations. However, adulteration become major trouble for users and industry for safety reasons and authentication of the plant with proper DNA marker is a major concern.METHODOLOGYDNA barcoding techniques and Phylogenetic analysis were employed to authenticate W. somnifera plant species using universal genetic markers. The markers were PCR amplified, sequenced and analyzed using BLAST-based and phylogeny-based identification methods.RESULTSThe BLAST result shows the percent identity (PI) of ITS1, ITS2, trnK, atpB, rbcL and matK was 100%, 100%, 100%, 97.59%, 100 and 99.20% respectively with the NCBI reference sequence. However, ITS1 and ITS2 show the maximum sequence similarity with W. somnifera of NCBI data. Phylogenetic analysis using NCBI data further supports the role of ITS in the discrimination of W. somnifera from closely related species.CONCLUSIONTherefore, the ITS gene may be considered promising a candidate for DNA barcoding for discrimination of W. somnifera from other species, its authentication and quality control.

16 Apr 2025·ACS Chemical Neuroscience

Exploration of the Therapeutic Potential of the Epigenetic Modulator Decitabine on 6-OHDA-Induced Experimental Models of Parkinson’s Disease

Article

Author: Pradhan, Rajesh ; Kumari, Shobha ; Dubey, Sunil Kumar ; Taliyan, Rajeev

Parkinson's disease (PD) poses a global menace, as the available treatment methods solely aim to mitigate symptoms. An effective strategy to address the pathogenesis of PD involves eliminating the accumulation of aggregated alpha-synuclein, emphasizing the role of epigenetics. Aberrant epigenetic changes significantly influence gene expression, which is pivotal in PD progression, impacting neuronal growth and degeneration. Epigenetic-related genes are regulated by histone modification and DNA methylation processes. Nevertheless, their significance in PD has not been confirmed. This research was carried out using both in vitro and in vivo approaches. In the in vitro investigations, N2A neuronal cell lines were utilized, and the neuroprotective effect of decitabine (DB) was observed at concentrations of 0.1 μM and 0.5 μM. In the in vivo study, PD induction led to significant motor deficits, which were notably ameliorated at the highest treatment dose. This improvement was accompanied by a marked attenuation of inflammatory mediators, including TNF-α, IL-6, IL-1β, and CRP levels. Additionally, there was a significant enhancement in antioxidative defense, evidenced by increased GSH (glutathione) levels and reduced oxidative stress marker NO (nitric oxide). Neurochemical analysis revealed a substantial rise in dopamine levels, a critical PD marker, alongside an elevation in BDNF, indicating neuroprotective effects. Furthermore, gene expression analysis indicated a notable upregulation in the mRNA expression of epigenetic genes and proteins linked to PD pathology. Histological assessments, including IHC, H&E, and CV staining of the substantia nigra, showed enhanced structural integrity following treatment. Collectively, these insights reveal DB's promise as a therapeutic solution for mitigating PD symptoms and pathology exacerbated by 6-OHDA.

01 Jan 2025·Journal of Drug Research in Ayurvedic Sciences

Pharmaceutical optimization and physicochemical analytical evaluation of Bhringamalaki Taila: A comprehensive study

Author: Kumar, Sanjay ; Rai, Rajiv Kumar ; Singh, Yashika ; Sharma, Karunanidhi

AbstractBACKGROUND:Ayurvedic medicated oils, utilized for various therapeutic purposes, are gaining popularity in the global cosmetics market for skincare and haircare. Among these, Bhringamalaki Taila (BT) is exceptional for its efficacy in treating hair ailments. The study aims to optimize the pharmaceutical process of BT and establish its physicochemical parameters to ensure quality and efficacy as well as to contribute novel insights into the unexplored areas within current research.METHODS:Botanicals, viz., Amla (Phyllanthus emblica L.), Bhringaraja [Eclipta prostrata (L.) L.], Yashtimadhu (Glycyrrhiza glabra L.), and Tila Taila (sesame oil) were authenticated. The BT was prepared through the following substeps: preparation of Bhringaraja Kwatha, Amla Swarasa, and Yashtimadhu Kalka, followed by Sneha Paka, a process that infuses active components into sesame oil via heating. The quality of BT was assessed through standardized physicochemical tests, i.e., specific gravity, refractive index, peroxide value, acid value, saponification value, unsaponifiable matter, rancidity test, and Ultraviolet–visible spectrophotometry.RESULTS:The preparation yielded 3.29 kg of BT from 3 kg of sesame oil. The organoleptic evaluation showed the characteristic properties of BT. The values of specific gravity, refractive index, peroxide value, acid value, saponification value, and unsaponifiable matter from physicochemical analysis were 0.9214%, 1.4753%, 2.8%, 4.6%, 188.62%, 56.15%, and 2.34%, respectively; rancidity was absent; and λmax was 279 nm.CONCLUSIONS:The present study highlights the critical application of traditional Ayurvedic principles in producing standardized, effective, and authentic Ayurvedic medicated oils such as Bhringamalaki Taila. This study optimizes the manufacturing process of BT and establishes the analytical parameters and standards, which will be beneficial for further research and manufacturing of BT. This approach fosters consumer trust and advances the quality of Ayurvedic medicines in the pharmaceutical industry, catering to a larger audience at global level.

100 Deals associated with Emami Ltd.

100 Translational Medicine associated with Emami Ltd.

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 08 Dec 2025

No data posted

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Emami Ltd.

Overview

Related

Corporation Tree

Pipeline

Pipeline Snapshot as of 08 Dec 2025

Deal

Translational Medicine

Profit

Grant & Funding(NIH)

Investment

Financing